Anne-Charlotte Rivière

Anne-Charlotte Rivière is a partner in Goodwin’s Life Sciences and Technology groups. Anne-Charlotte focuses on transactions in the life sciences and technology sectors, acting for companies at all stages of development, as well as investors and management teams.

She guides these companies beyond their equity financing on all their strategic challenges including collaboration, mergers and acquisitions, public offerings and reorganization.

Anne-Charlotte also assists private equity funds in their leveraged buy-out (LBO) transactions in several sectors including the healthcare and other regulated sectors.

She is also regularly involved in secondary transactions.

Prior to joining Goodwin in 2021, Anne-Charlotte was a partner at Dechert and previously worked in other international law firms.

Anne-Charlotte’s recent representative transactions include advising:

Life Sciences

• AlgoTx, a start-up developing a treatment for neuropathic pain caused by chemotherapy, as part of its €19 million Series B funding round.
• Cathay Health in its investment in the €51 million Series B financing round of Moon Surgical, a Paris-based, early-stage medical device company, developing a surgical robot for laparoscopy assistance.
• Karista:
  • in the €3.7 million financing of RebrAIn, a Bordeaux-based company that enables precise targeting for DBS treatment for patients suffering from severe Parkinson's or essential tremor disease.
  • and YZR Capital in the €4 million Series Seed financing of Deemea, a French company which creates and develops an AI-driven platform for the processing and interpretation of radiologic medical imaging.
• Kurma Partners in the €6.2 million Series Seed financing of Spotlight Medical, a spinoff of Institut Curie which aims at transforming cancer treatment using advanced artificial intelligence (AI).
• Mablink Bioscience, a biotechnology company that seeks to bring new and better treatment options to cancer patients with unmet needs, in its sale to Lilly & Co.
• SpeedInvest in the €3 million Series Seed financing of Orakl Oncology, a science-based startup leveraging a collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer.
• Stilla Technologies, a medical technology company, in its $26.5 million Series C financing round. 
• TRICares, a dedicated medical device company located in Paris, and Munich, which aims to provide safer, less invasive treatment options to improve patient outcome, in its $50 million Series D financing.

Technology

• Ascendance Flight Technologies, a sustainable flight solutions provider, in its €21 million Series A fundraising.
• Alven Capital Partners:
  • in its investment in the €25 million Series B financing of Stoïk, an insurtech specializing in cyber insurance for businesses.
  • in the €7 million Series A financing of Kestra Technologies, a unified orchestration platform designed to simplify and automate business-critical workflows, allowing users to manage them as code or through a user interface. 
• Bpifrance in the €20 million Series A Financing of Beyond Aero, a French startup, based in Toulouse, developing long range hydrogen-fueled aircraft.
• H Company, a French AI startup, in its $220 million Series Seed financing.
• Micropep Technologies, a biotechnology company engaged in developing innovative plant stimulation and protection solutions based on peptides, in its $29 million Series B financing. 
• Confidential investors in the €500 million Series A financing round of Mistral.AI, a French-based company developing an AI-powered data entry system for companies.
• SpeedInvest and Daphni in the $25 million Series A financing of Flow48, a FinTech operating in the MENA region, which provides revenue-based financing services to small and medium companies as an alternative lending model.

LBO AND OTHER TRANSACTIONS

• Eurazeo in the sale of Péters Surgical, a leading global provider of specialty surgical sutures, to Advanced Medical Solutions Group plc.

Anne-Charlotte is consistently recognized as a leader in her field by International and French preeminent, peer-reviewed publications.

• Ranked in Band 3 in Private Equity: Venture Capital and in Pharma/Life Sciences (Corporate) in the last edition of the Chambers France guide
• Ranked as Next Generation Partner in Healthcare and Life Sciences and Private Equity: Venture/Growth Capital in the last edition of the Legal 500 EMEA guide
• Recommended in Venture Capital Law, Private Equity Law and Mergers and Acquisitions Law in the last edition of Best Lawyers France

As a successful woman professional, Anne-Charlotte is committed to promoting Women leadership both inside and outside of the firm. As such, she co-leads Goodwin’s Paris Women’s Initiative Committee and has been driving women-oriented mentoring sessions, client initiatives and networking opportunities.

Anne-Charlotte’s recent publications and speaking engagement include:

Publications

• Co-Author (with Inès Louguar), “Vers une nouvelle ère de la mode écoresponsable,” Maddyness, December 2023
• Interview, “Silicon Valley Bank, 6 mois après : qu’est-ce qui a changé pour les startups?,” Maddyness, October 2023
• Author, “Entre optimisme et réalisme, un équilibre difficile à trouver pour les entrepreneurs,” Maddyness, August 2023
• Interview, “Fermeture de la Silicon Valley Bank : quel impact pour la France?,” Maddyness, March 2023
• Co-Author (with Julie Messerig), “Bridge, entre perte d’attractivité et nécessité,” Biotech Finance, February 2023
• Co-Author (with Louis Taslé d’Héliand), “Dual Track: un et un font trois,” Biotech Finance, January 2023
• Co-Author (with Céline Domenget-Morin), “Biotechs, medtechs: ce qui ne me tue pas me fortifie ?,” Les Echos, January 2023
• Co-Author (with Sarah Fleury), “Property Sciences, un marché en devenir,” Business Immo, February 2022
• Interview, “L’Europe renforce le contrôle des rachats des stratégiques BioTech,” Maddyness, April 2020
• Interview, “Biotechs : décryptage du nouveau régime de contrôle des investissements étrangers,” Le Point, November 2020

Speaking Engagements

• Panelist in the session, “Key Collaboration and Financing Issues during the Covid-19 Pandemic,” HealthTech Innovation Days, October 2020